Description

Pioglitazone Hydrochloride, a thiazolidinedione derivative, is widely studied for its role as a peroxisome proliferator-activated receptor gamma (PPAR-?) agonist. It helps enhance insulin sensitivity in muscle and adipose tissues by modulating gene expression involved in glucose and lipid metabolism.

The Aiting formulation delivers 15mg per tablet and is provided in 2 blister packs of 7 tablets (14 total). It is approved under China NMPA H20040267 and is widely used in type 2 diabetes research models and insulin resistance assays.

?? For research use only. Not for human or veterinary use.

Product Specifications

Mechanism & Research Applications

Pioglitazone is a selective PPAR-? agonist, modulating transcription of insulin-responsive genes involved in glucose and lipid metabolism. It enhances insulin sensitivity, reduces hepatic glucose production, and improves lipid profiles in insulin-resistant models.

This compound is commonly used in:

• Type 2 diabetes mellitus research

• Metabolic syndrome modeling

• Insulin resistance studies

• Adipocyte differentiation assays

• Hepatic steatosis and NASH research

Observed Effects in Research Models

In preclinical settings, pioglitazone may show:

• Improved insulin sensitivity in test models

• Altered adiponectin and leptin expression

• Weight gain and fluid retention (dose-dependent)

• Hepatic enzyme modulation

Standard monitoring protocols should be followed during administration.

Safety & Handling

• Use Restriction: For laboratory research use only.

• Protective Equipment: Gloves, lab coat, goggles

• Storage: Sealed container, <25°C

• Disposal: Comply with institutional and local regulations for pharmaceutical waste

Research Use Disclaimer

This product is exclusively intended for laboratory research use. It is not approved for clinical, therapeutic, diagnostic, or veterinary applications. Misuse may pose health or legal risks. Users must comply with institutional biosafety guidelines.